Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sutacimig for prophylaxis in glanzmann thrombasthenia: A trial in progress

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPaul SaultierFXFrederico XavierAAAndrea Artoni

Discussion

Loading...

Member takes

Overview

Open-label study evaluates the safety, tolerability, and efficacy of a bispecific antibody in reducing bleeding events in Glanzmann thrombasthenia.

Key Points

  • Sutacimig shows promising potential to improve hemostasis and reduce bleeding events in patients with Glanzmann thrombasthenia.
  • Key outcomes include safety, tolerability, and efficacy metrics through pharmacokinetics and pharmacodynamics assessments.
  • Observational study assessing the bispecific antibody's impact on bleeding frequency and severity over time.
  • These findings support the need for effective prophylactic therapies in preventing bleeding episodes and managing iron deficiency anemia.

Cite This Study

Saultier et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e323https://doi.org/10.1182/blood-2025-8232
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sutacimig, a novel bispecific antibody for prophylactic treatment of glanzmann thrombasthenia: Analysis of a Phase 2 study2025 · 2 citations
  2. 2Enhancing hemostasis in glanzmann thrombasthenia via protein S inhibition2025
  3. 3Intraoperative Bleeding During Mammoplasty and Dermolipectomy: A Case of Glanzmann's Thrombasthenia2025
  4. 4European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice2025
  5. 5Mixed Chimerism and Clinical Outcome of Hematopoietic Stem Cell Transplantation in Glanzmann Thrombasthenia: Experience on 2 Siblings and Literature Review2025